Retinal Microanatomy in Retinopathy of Prematurity (BabySTEPS2)
Duke University · with University of Pennsylvania, National Eye Institute (NEI) · NCT04995341
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Any age listed · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 236
- US sites recruiting
- 1
- Study start
- August 16, 2021
- Record last updated
- May 22, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Retinopathy of prematurity (ROP) is a disorder of development of the neural retina and its vasculature that can impact vision in vulnerable preterm neonates for a lifetime. This study tests high-speed optical coherence tomography (OCT) technology compared to conventional color photographs at the bedside of very preterm infants in the intensive care nursery, to characterize previously unseen abnormalities that can predict a need for referral for ROP treatment, or poor visual or neurological development later in life, up to pre-school age. Our long-term goal is to help improve preterm infant health and vision via objective bedside imaging and analysis that characterizes early critical indicators of ROP, and poor visual function and neurological development, which will rapidly translate to better early intervention and improved future care.
Being studied: Investigational ultracompact OCT and OCTA system; retinal photographs
Conditions: Retinopathy of Prematurity
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Children previously enrolled in BabySTEPS1 (Pro00069721) that have already consented to being contacted for this school age follow on study, Cohort 1 only
- Parent/Legal Guardian is able and willing to consent to study participation with follow up approximately between 4.5 and 5 years of age (consent available in Spanish* and English) (SA 1 only)
- Parent/Legal Guardian is able and willing to consent to study participation for the infant (SA 2 and 2c only)
- Infant/child undergoing clinically-indicated examination under anesthesia that may or may not have eye pathology (SA 2 only)
- Infant inborn or outborn at (SA 2 only):
- Duke Hospital (Years 1, 2 and 3) with birth weight ≤1000 grams, and/or 20 0/7 to 28/ 6/7 (\<29 weeks) gestational age
- Duke Hospital (Years 1, 2 and 3) at high risk to require treatment for ROP irrespective of birth weight and gestational age (e.g. pre-plus, severe ROP in zone 1, APROP, etc.)
- Duke Regional Hospital (Years 4 and 5) that meets the American Association of Pediatrics eligibility of ROP screening (Infants with a birth weight of ≤1500 g or gestational age of 30 weeks)
- Adults (over the age of 18 years) that may or may not have eye pathology (SA 2 only)
Exclusion Criteria
- Participant or Parent/Legal Guardian unwilling or unable to provide consent
- Adult participant or infant/child has a health or eye condition that preclude eye examination or retinal imaging (e.g. corneal opacity such as with Peter's anomaly or cataract) (SA2 only)
- Infant has a health condition, other than prematurity, that has a profound impact on brain development (e.g. anencephaly) (SA2 only)
Recruiting US locations
Duke University Eye Center
Durham, NC 27705
Site contact: Cynthia A Toth, MD · 9196845631 · cynthia.toth@duke.edu
Study contacts (from the official record)
- Cynthia A Toth, MD · 919-684-5631 · cynthia.toth@duke.edu
- Michelle N McCall, MCAPM, BA · 919-684-0544 · michelle.mccall@duke.edu
Similar studies in North Carolina
All healthy volunteers studies in North Carolina →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Nalmefene Implant in Healthy Subjects
ReacX Pharmaceuticals, Inc.
- Location
- Morrisville, NC
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
IAP-086-1: A Phase 1 Single Ascending Dose First-Time in Human Study
University of North Carolina, Chapel Hill
- Location
- Chapel Hill, NC + 1 other US site
- Eligibility basics
- Ages 18–70
- RecruitingHealthy volunteers
Breastfeeding Intervention to Prevent Obesity Among Children
University of North Carolina, Greensboro
- Location
- Greensboro, NC + 1 other US site
- Eligibility basics
- Ages 0 mo+
- RecruitingHealthy volunteersPhase 1/Phase 2
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
Novartis Pharmaceuticals
- Location
- Charlotte, NC + 7 other US sites
- Eligibility basics
- Ages 12–55